US BioTek Laboratories Acquires RealTime Laboratories

Discovery Life Sciences Acquires ReachBio Research Labs

April 11, 2023

Biotechnology

Discovery Life Sciences has acquired Seattle-based ReachBio Research Labs to expand its cell biology, toxicology and drug screening capabilities. The acquisition strengthens Discovery's preclinical development and multi-omics service offering, enabling customers to access a broader set of predictive cell-based assays for hematologic diseases, immunology, oncology and cell & gene therapy programs.

R-Biopharm AG Acquires AusDiagnostics

June 7, 2022

Biotechnology

German biotechnology company R-Biopharm AG has acquired Australian molecular diagnostics manufacturer AusDiagnostics. The purchase adds AusDiagnostics' multiplex MT-PCR platforms, extraction reagents and laboratory automation capabilities to R-Biopharm's clinical diagnostics portfolio, supporting capability expansion and internationalization into new clinical, veterinary and applied testing markets.

BioAgilytix Acquires 360biolabs and MicroConstants

October 14, 2021

Healthcare Services

BioAgilytix Labs, LLC acquired Australia-based 360biolabs and US-based MicroConstants to expand its global footprint and bioanalytical capabilities, including LC/MS/MS, virology and immunology expertise. The deals (360biolabs subject to FIRB approval) add capacity in Melbourne and Brisbane and establish BioAgilytix San Diego, strengthening support for first-in-human and early-phase clinical trials across major geographies.

Labcorp Acquires Toxikon Corporation

November 18, 2021

Healthcare Services

Labcorp has acquired Toxikon Corporation, a Bedford, Massachusetts-based contract research organization that provides nonclinical in vivo and in vitro testing for pharmaceutical, biotech and medical device clients. The acquisition expands Labcorp Drug Development's nonclinical testing capabilities and creates a strategic Boston-area footprint; Toxikon reported approximately $40 million in annual revenue and the deal closed in December 2021.

Heska Corporation Acquires Biotech Laboratories U.S.A. LLC to Enter Rapid Assay Veterinary Diagnostics Market

September 1, 2021

Medical Devices

Heska Corporation acquired majority ownership of Biotech Laboratories U.S.A. LLC, a Rockville, Maryland developer of rapid point-of-care lateral flow diagnostics for animals. The acquisition (closed Sept. 1, 2021) brings Biotech's rapid assay pipeline, manufacturing expertise and IP into Heska's product portfolio as the company moves to launch a full line of single-use rapid assays for veterinarians and livestock producers.

bioMérieux Acquires Specific Diagnostics

April 12, 2022

Medical Devices

bioMérieux has agreed to acquire Specific Diagnostics, a U.S.-based developer of the SPECIFIC REVEAL Rapid AST system, to strengthen its sepsis and antimicrobial stewardship portfolio. bioMérieux will acquire 100% of Specific Diagnostics for a consideration equivalent to 3.3% of bioMérieux's market capitalization as of April 11, 2022, paid in cash and newly issued shares; the deal was expected to close by the end of Q2 2022 subject to regulatory approvals.